Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

BI2536 induces mitotic catastrophe and radiosensitization in human oral cancer cells

(2018) Chieh-Yuan Cheng et al.   Oncotarget

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ribociclib for HR-Positive, Advanced Breast Cancer

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer

(2017) Esther S. Kim et al.   Targeted Oncology

Targeted therapies for gastric cancer: failures and hopes from clinical trials

(2017) Maria Apicella et al.   Oncotarget

PLK1 Activation in Late G2 Sets Up Commitment to Mitosis

(2017) Lilia Gheghiani et al.   Cell Reports

Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

(2016) Rosie Elizabeth Ann Gutteridge et al.   MOLECULAR CANCER THERAPEUTICS

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

(2016) Jieqiong Wang et al.   Nature Communications

The Bub1–Plk1 kinase complex promotes spindle checkpoint signalling through Cdc20 phosphorylation

(2016) Luying Jia et al.   Nature Communications

TP53 mutations, expression and interaction networks in human cancers

(2016) Xiaosheng Wang et al.   Oncotarget

Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells

(2015) Minji Choi et al.   CANCER LETTERS

Akt: a new activation mechanism

(2014) Yuan Gao et al.   CELL RESEARCH

Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus

(2014) Pengda Liu et al.   NATURE

Identification of potential synthetic lethal genes to p53 using a computational biology approach

(2013) Xiaosheng Wang et al.   BMC Medical Genomics

Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer

(2013) Hyun Seok Kim et al.   CELL

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

(2012) A. Frost et al.   Current Oncology

Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates

(2010) Randy Suryadinata et al.   BIOSCIENCE REPORTS

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

The Roles of Cyclin A2, B1, and B2 in Early and Late Mitotic Events

(2010) Delquin Gong et al.   MOLECULAR BIOLOGY OF THE CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL